SUCLA2

Across TCGA pan-cancer cohorts, SUCLA2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SUCLA2 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SUCLA2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUCLA2 expression acts as an unfavorable survival marker.

BLCA, COAD, and BRCA are the cancer types where SUCLA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.090	0.572	<.001	24	view →
COAD	DFS	Median	All	0.240	0.699	.005	15	view →
BRCA	OS	Median	All	0.159	0.579	.017	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SUCLA2–BLCA (DFS)

Open the BLCA breakdown →